Protokinetix Inc (PKTX) 0.0628 $PKTX
ProtoKinetix' 2nd Quarter Scientific Update
BusinessWire - Thu Jul 14, 8:30AM CDT
ProtoKinetix, Incorporated (OTCQB
KTX) (the "Company" or "ProtoKinetix"
(www.protokinetix.com) is pleased to provide the following corporate update to its stockholders:
ProtoKinetix' AAGP(TM) has been Published in the Journal of Tissue Engineering and Regenerative Medicine
BusinessWire - Tue Jun 07, 10:00AM CDT
ProtoKinetix, Incorporated (OTCQBKTX) (the "Company" or "ProtoKinetix" (www.protokinetix.com) is pleased to announce that a paper submitted by Dr. Kevin Gregory-Evans on ProtoKinetix' AAGP(TM) has been published in the Journal of Tissue Engineering and Regenerative Medicine and is available online at:
ProtoKinetix Updates Progress Toward Clinical Trial Application for AAGP(TM)
BusinessWire - Thu May 12, 9:00AM CDT
ProtoKinetix, Incorporated (OTCQB: PKTX) (the "Company" or "ProtoKinetix" (www.protokinetix.com) is pleased to update its stockholders on the progress that it has made toward the application to conduct clinical trials in Canada with Health Canada.
AAGP(TM) Improves Results in Stem Cells Transplanted in Retina Tissue by 300%
BusinessWire - Mon May 02, 9:41AM CDT
ProtoKinetix, Incorporated (OTCQBKTX) (the "Company" or "ProtoKinetix" (www.protokinetix.com) is pleased to announce that a paper submitted by Dr. Kevin Gregory-Evans on ProtoKinetix' AAGP(TM) has been accepted by the Journal of Tissue Engineering and Regenerative Medicine for publication. The date of publication is unknown at this time but should be available online in advance of the printed version. AAGP(TM), an antifreeze glycopeptide, has been demonstrated to significantly improve the viable yield of stem cells transplanted in retinal tissue at the University of British Columbia under the guidance of Dr. Kevin Gregory-Evans.
ProtoKinetix Outlines Steps to Clinical Trial Application for AAGP(TM)
BusinessWire - Tue Apr 26, 8:00AM CDT
ProtoKinetix, Incorporated (OTCQB: PKTX) (the "Company" or "ProtoKinetix" (www.protokinetix.com) outlines the steps to be completed for the application to conduct a clinical trial in Canada.
ProtoKinetix Corporate Update
BusinessWire - Tue Jan 05, 2:24PM CST
ProtoKinetix, Incorporated (OTCQBKTX) (the "Company" or "ProtoKinetix" (www.protokinetix.com) is pleased to provide the following corporate update to its stockholders:
AAGP(TM) Found to Significantly Improve Islet Cell Transplantation in Type 1 Diabetes Patients
BusinessWire - Thu Dec 17, 12:30PM CST
ProtoKinetix, Incorporated (OTCQBKTX) (the "Company" or "ProtoKinetix" (www.protokinetix.com) is pleased to announce that their molecule, AAGP(TM), an antifreeze glycopeptide that mimics a naturally occurring glycoprotein found in Arctic fish is helping to significantly improve the efficacy of Cell Transplant Treatments for diabetes - a procedure that transplants insulin producing islet to render them insulin independent for periods of time.
ProtoKinetix Completes Private Placement
BusinessWire - Mon Nov 09, 8:25AM CST
ProtoKinetix, Incorporated (OTCQB: PKTX) (the "Company" or "ProtoKinetix" (www.protokinetix.com) is pleased to announce that it has completed a non-brokered private placement (the "Offering" that closed on November 6, 2015. A total of $200,000 was raised with the offering of 5,000,000 units purchased. Each unit is equivalent to one share of common stock of the Company at $0.04 per share and a non-detachable warrant for one share of common stock of the Company exercisable, on or before December 28, 2015, at $0.04 per share.
ProtoKinetix Begins Testing Diabetic Mice with AAGP(TM) at the University of Alberta
BusinessWire - Fri Sep 18, 9:00AM CDT
ProtoKinetix, Incorporated (OTC: PKTX) (the "Company" or "ProtoKinetix" (www.protokinetix.com) is pleased to announce that it has begun testing NOD (Non Obese Diabetic) mice with its AAGP(TM) molecule at the James Shapiro laboratory at the University of Alberta.
ProtoKinetix' AAGP(TM) to Be Presented at the Congress of the International Pancreas and Islet Transplant Association
BusinessWire - Thu Sep 10, 8:00AM CDT
ProtoKinetix, Incorporated (OTC: PKTX) (the "Company" or "ProtoKinetix" (www.protokinetix.com) is pleased to announce that AAGP(TM) will be presented at the 2015 Joint Congress of the IPITA-IXA-CTS on Monday, November 16, 2015. The Joint Congress of the International Pancreas and Islet Transplant Association (IPITA), the International Xenotransplantation Association (IXA) and the Cell Transplant Society (CTS) to be held in Melbourne, Australia, 15-19 November 2015.
ProtoKinetix Reports on Its Strong Collaboration with the James Shapiro Laboratory at the University of Alberta
BusinessWire - Tue Aug 04, 8:15AM CDT
ProtoKinetix, Incorporated (OTC: PKTX) (the "Company" or "ProtoKinetix" (www.protokinetix.com) is pleased to report on its collaboration with the James Shapiro laboratory at the University of Alberta. The sole intention of the collaboration is to develop a commercial product pipeline of therapeutic applications for the AAGP(TM) family of molecules.
ProtoKinetix Announces Appointment of New Director and Provides Corporate Update
BusinessWire - Wed Jul 01, 6:17PM CDT
ProtoKinetix, Incorporated (OTC: PKTX) (the "Company" or "ProtoKinetix" (www.protokinetix.com) is pleased to announce that Edward P. McDonough was appointed to the company's board of directors. The Company has issued a two-year option for 1,000,000 shares of common stock subject to vesting exercisable at $0.10 per share to Mr. McDonough in connection with his appointment to the Board and for services to the Company.
ProtoKinetix Upgrades to OTCQB
PR Newswire - Mon Jun 08, 8:25AM CDT
ProtoKinetix, Incorporated (OTCQB: PKTX) (the "Company" or "ProtoKinetix" (www.protokinetix.com) is pleased to announce that ProtoKinetix began trading today on the OTCQB® Venture Marketplace under the symbol "PKTX." The Company was formerly trading on the OTC Pink® marketplace under the same symbol.
CEO Clarence Smith Reports on Edmonton Meetings with Dr. James Shapiro and his Team
BusinessWire - Fri Jun 05, 8:30AM CDT
ProtoKinetix, Incorporated (OTC: PKTX) (the "Company" or "ProtoKinetix" (www.protokinetix.com) is pleased to announce that CEO Clarence Smith recently returned from visiting Dr. James Shapiro at the University of Alberta. Mr. Smith met with Dr. Shapiro and his impressive team, including Dr. Boris Gala-Lopez. As previously announced, the Company has been heavily involved with the James Shapiro Laboratory for the last 24-months. Dr. Shapiro's team has conducted extensive tests on islet cell transplantation using the AAGP(TM) molecule for the treatment of diabetes using AAGP(TM). Mr. Smith was impressed with the program and gratified that AAGP(TM) was proving to be a central element in the research.
ProtoKinetix Announces Share Issuance
BusinessWire - Wed May 06, 3:53PM CDT
ProtoKinetix, Incorporated (OTC: PKTX) (the "Company" or "Protokinetix" (www.protokinetix.com) is pleased to announce that it has completed a private placement (the "Offering" for gross proceeds of $155,000. The Company has issued 1,937,500 shares of common stock at a price of $0.08 per share.
ProtoKinetix Accepts Director's Resignation
BusinessWire - Fri May 01, 10:55AM CDT
ProtoKinetix, Incorporated (OTC: PKTX) (www.protokinetix.com) ("ProtoKinetix" or the "Company" announces that it has received and accepted the resignation of Mr. Peter K. Jensen as a Director of the Company effective as of April 30, 2015. Mr. Jensen's resignation was due to personal reasons, and not as the result of any disagreement with the Company practices or policies.
ProtoKinetix Announces Acquisition of Patents
BusinessWire - Mon Apr 27, 12:20PM CDT
ProtoKinetix, Incorporated (OTCKTX) (www.protokinetix.com) ("ProtoKinetix" or the "Company" is pleased to announce that it has completed the acquisition of a portion of certain patents and all rights associated therewith (the "Patent Rights" pursuant to the Technology Transfer Agreement entered into with Grant Young on or about April 22, 2015. In exchange for the Patent Rights, Mr. Young will receive $10,000 in cash and a five-year warrant to purchase 6,000,000 shares of the Company's common stock at an exercise price of $0.10 per share.
ProtoKinetix Announces Consulting Agreements
BusinessWire - Fri Apr 03, 1:27PM CDT
ProtoKinetix, Incorporated (OTC: PKTX) (the "Company" or "Protokinetix" (www.protokinetix.com) is pleased to announce that it has entered into consulting agreements with Clarence E. Smith, President and Chief Executive Officer of the Company, and Susan M. Woodward, Chief Financial Officer of the Company.
ProtoKinetix' 2nd Quarter Scientific Update
BusinessWire - Thu Jul 14, 8:30AM CDT
ProtoKinetix, Incorporated (OTCQB
KTX) (the "Company" or "ProtoKinetix" (www.protokinetix.com) is pleased to provide the following corporate update to its stockholders: ProtoKinetix' AAGP(TM) has been Published in the Journal of Tissue Engineering and Regenerative Medicine
BusinessWire - Tue Jun 07, 10:00AM CDT
ProtoKinetix, Incorporated (OTCQB
KTX) (the "Company" or "ProtoKinetix" (www.protokinetix.com) is pleased to announce that a paper submitted by Dr. Kevin Gregory-Evans on ProtoKinetix' AAGP(TM) has been published in the Journal of Tissue Engineering and Regenerative Medicine and is available online at: ProtoKinetix Updates Progress Toward Clinical Trial Application for AAGP(TM)
BusinessWire - Thu May 12, 9:00AM CDT
ProtoKinetix, Incorporated (OTCQB: PKTX) (the "Company" or "ProtoKinetix"
(www.protokinetix.com) is pleased to update its stockholders on the progress that it has made toward the application to conduct clinical trials in Canada with Health Canada. AAGP(TM) Improves Results in Stem Cells Transplanted in Retina Tissue by 300%
BusinessWire - Mon May 02, 9:41AM CDT
ProtoKinetix, Incorporated (OTCQB
KTX) (the "Company" or "ProtoKinetix" (www.protokinetix.com) is pleased to announce that a paper submitted by Dr. Kevin Gregory-Evans on ProtoKinetix' AAGP(TM) has been accepted by the Journal of Tissue Engineering and Regenerative Medicine for publication. The date of publication is unknown at this time but should be available online in advance of the printed version. AAGP(TM), an antifreeze glycopeptide, has been demonstrated to significantly improve the viable yield of stem cells transplanted in retinal tissue at the University of British Columbia under the guidance of Dr. Kevin Gregory-Evans. ProtoKinetix Outlines Steps to Clinical Trial Application for AAGP(TM)
BusinessWire - Tue Apr 26, 8:00AM CDT
ProtoKinetix, Incorporated (OTCQB: PKTX) (the "Company" or "ProtoKinetix"
(www.protokinetix.com) outlines the steps to be completed for the application to conduct a clinical trial in Canada. ProtoKinetix Corporate Update
BusinessWire - Tue Jan 05, 2:24PM CST
ProtoKinetix, Incorporated (OTCQB
KTX) (the "Company" or "ProtoKinetix" (www.protokinetix.com) is pleased to provide the following corporate update to its stockholders: AAGP(TM) Found to Significantly Improve Islet Cell Transplantation in Type 1 Diabetes Patients
BusinessWire - Thu Dec 17, 12:30PM CST
ProtoKinetix, Incorporated (OTCQB
KTX) (the "Company" or "ProtoKinetix" (www.protokinetix.com) is pleased to announce that their molecule, AAGP(TM), an antifreeze glycopeptide that mimics a naturally occurring glycoprotein found in Arctic fish is helping to significantly improve the efficacy of Cell Transplant Treatments for diabetes - a procedure that transplants insulin producing islet to render them insulin independent for periods of time. ProtoKinetix Completes Private Placement
BusinessWire - Mon Nov 09, 8:25AM CST
ProtoKinetix, Incorporated (OTCQB: PKTX) (the "Company" or "ProtoKinetix"
(www.protokinetix.com) is pleased to announce that it has completed a non-brokered private placement (the "Offering" that closed on November 6, 2015. A total of $200,000 was raised with the offering of 5,000,000 units purchased. Each unit is equivalent to one share of common stock of the Company at $0.04 per share and a non-detachable warrant for one share of common stock of the Company exercisable, on or before December 28, 2015, at $0.04 per share. ProtoKinetix Begins Testing Diabetic Mice with AAGP(TM) at the University of Alberta
BusinessWire - Fri Sep 18, 9:00AM CDT
ProtoKinetix, Incorporated (OTC: PKTX) (the "Company" or "ProtoKinetix"
(www.protokinetix.com) is pleased to announce that it has begun testing NOD (Non Obese Diabetic) mice with its AAGP(TM) molecule at the James Shapiro laboratory at the University of Alberta. ProtoKinetix' AAGP(TM) to Be Presented at the Congress of the International Pancreas and Islet Transplant Association
BusinessWire - Thu Sep 10, 8:00AM CDT
ProtoKinetix, Incorporated (OTC: PKTX) (the "Company" or "ProtoKinetix"
(www.protokinetix.com) is pleased to announce that AAGP(TM) will be presented at the 2015 Joint Congress of the IPITA-IXA-CTS on Monday, November 16, 2015. The Joint Congress of the International Pancreas and Islet Transplant Association (IPITA), the International Xenotransplantation Association (IXA) and the Cell Transplant Society (CTS) to be held in Melbourne, Australia, 15-19 November 2015. ProtoKinetix Reports on Its Strong Collaboration with the James Shapiro Laboratory at the University of Alberta
BusinessWire - Tue Aug 04, 8:15AM CDT
ProtoKinetix, Incorporated (OTC: PKTX) (the "Company" or "ProtoKinetix"
(www.protokinetix.com) is pleased to report on its collaboration with the James Shapiro laboratory at the University of Alberta. The sole intention of the collaboration is to develop a commercial product pipeline of therapeutic applications for the AAGP(TM) family of molecules. ProtoKinetix Announces Appointment of New Director and Provides Corporate Update
BusinessWire - Wed Jul 01, 6:17PM CDT
ProtoKinetix, Incorporated (OTC: PKTX) (the "Company" or "ProtoKinetix"
(www.protokinetix.com) is pleased to announce that Edward P. McDonough was appointed to the company's board of directors. The Company has issued a two-year option for 1,000,000 shares of common stock subject to vesting exercisable at $0.10 per share to Mr. McDonough in connection with his appointment to the Board and for services to the Company. ProtoKinetix Upgrades to OTCQB
PR Newswire - Mon Jun 08, 8:25AM CDT
ProtoKinetix, Incorporated (OTCQB: PKTX) (the "Company" or "ProtoKinetix"
(www.protokinetix.com) is pleased to announce that ProtoKinetix began trading today on the OTCQB® Venture Marketplace under the symbol "PKTX." The Company was formerly trading on the OTC Pink® marketplace under the same symbol. CEO Clarence Smith Reports on Edmonton Meetings with Dr. James Shapiro and his Team
BusinessWire - Fri Jun 05, 8:30AM CDT
ProtoKinetix, Incorporated (OTC: PKTX) (the "Company" or "ProtoKinetix"
(www.protokinetix.com) is pleased to announce that CEO Clarence Smith recently returned from visiting Dr. James Shapiro at the University of Alberta. Mr. Smith met with Dr. Shapiro and his impressive team, including Dr. Boris Gala-Lopez. As previously announced, the Company has been heavily involved with the James Shapiro Laboratory for the last 24-months. Dr. Shapiro's team has conducted extensive tests on islet cell transplantation using the AAGP(TM) molecule for the treatment of diabetes using AAGP(TM). Mr. Smith was impressed with the program and gratified that AAGP(TM) was proving to be a central element in the research. ProtoKinetix Announces Share Issuance
BusinessWire - Wed May 06, 3:53PM CDT
ProtoKinetix, Incorporated (OTC: PKTX) (the "Company" or "Protokinetix"
(www.protokinetix.com) is pleased to announce that it has completed a private placement (the "Offering" for gross proceeds of $155,000. The Company has issued 1,937,500 shares of common stock at a price of $0.08 per share. ProtoKinetix Accepts Director's Resignation
BusinessWire - Fri May 01, 10:55AM CDT
ProtoKinetix, Incorporated (OTC: PKTX) (www.protokinetix.com) ("ProtoKinetix" or the "Company"
announces that it has received and accepted the resignation of Mr. Peter K. Jensen as a Director of the Company effective as of April 30, 2015. Mr. Jensen's resignation was due to personal reasons, and not as the result of any disagreement with the Company practices or policies. ProtoKinetix Announces Acquisition of Patents
BusinessWire - Mon Apr 27, 12:20PM CDT
ProtoKinetix, Incorporated (OTC
KTX) (www.protokinetix.com) ("ProtoKinetix" or the "Company" is pleased to announce that it has completed the acquisition of a portion of certain patents and all rights associated therewith (the "Patent Rights" pursuant to the Technology Transfer Agreement entered into with Grant Young on or about April 22, 2015. In exchange for the Patent Rights, Mr. Young will receive $10,000 in cash and a five-year warrant to purchase 6,000,000 shares of the Company's common stock at an exercise price of $0.10 per share. ProtoKinetix Announces Consulting Agreements
BusinessWire - Fri Apr 03, 1:27PM CDT
ProtoKinetix, Incorporated (OTC: PKTX) (the "Company" or "Protokinetix"
(www.protokinetix.com) is pleased to announce that it has entered into consulting agreements with Clarence E. Smith, President and Chief Executive Officer of the Company, and Susan M. Woodward, Chief Financial Officer of the Company. 
